Gunnels Wood Road

Summary

Organization: Gunnels Wood Road
Country: UK

Top Publications

  1. ncbi Changes in vascular dynamics of the adult rat testis leading to transient accumulation of seminiferous tubule fluid after administration of a novel 5-hydroxytryptamine (5-HT) agonist
    Jacqui Piner
    GlaxoSmithKline, Ware, Hertfordshire, SG12 ODP, UK
    Reprod Toxicol 16:141-50. 2002
  2. ncbi Synergy between combinatorial chemistry and de novo design
    A R Leach
    Glaxo Wellcome Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom
    J Mol Graph Model 18:358-67, 526. 2000
  3. ncbi Bioavailability of orally administered micronised fluticasone propionate
    C Falcoz
    Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex, England
    Clin Pharmacokinet 39:9-15. 2000
  4. ncbi Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma
    P T Daley-Yates
    Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex, England
    Clin Pharmacokinet 39:39-45. 2000
  5. pmc Characterization of [(3)H]-CGP54626A binding to heterodimeric GABA(B) receptors stably expressed in mammalian cells
    A Green
    Receptor Systems Unit, Glaxo Wellcome Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY
    Br J Pharmacol 131:1766-74. 2000
  6. pmc Use of two-dimensional gel electrophoresis to measure changes in synovial fluid proteins from patients with rheumatoid arthritis treated with antibody to CD4
    M A Smith
    Immunopathology, Glaxo Wellcome Research and Development plc, Stevenage, Herts SG1 2NY, United Kingdom
    Clin Diagn Lab Immunol 8:105-11. 2001
  7. ncbi Pyridoxal phosphate de-activation by pyrroline-5-carboxylic acid. Increased risk of vitamin B6 deficiency and seizures in hyperprolinemia type II
    R D Farrant
    Physical Sciences, GlaxoWellcome Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom
    J Biol Chem 276:15107-16. 2001
  8. ncbi Epidemiology in the pharmaceutical industry: a perspective for infectious diseases
    N J Robinson
    Worldwide Epidemiology, GlaxoWellcome Research and Development, Greenford Road, Greenford, Middlesex UB6 OHE, UK
    Stat Med 19:3193-8. 2000
  9. ncbi Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation
    D A Hall
    Receptor Pharmacology Unit, In Vitro Pharmacology Department, Medicines Research Centre, Glaxo Wellcome Research and Development, Stevenage, Hertfordshire, United Kingdom
    Mol Pharmacol 58:1412-23. 2000
  10. ncbi Loss of epithelial integrity resulting from E-cadherin dysfunction predisposes airway epithelial cells to adenoviral infection
    Y Man
    Cell Biology Department and Clinical Virology Department, Medicines Research Centre, GlaxoWellcome, Stevenage, United Kingdom
    Am J Respir Cell Mol Biol 23:610-7. 2000

Scientific Experts

Detail Information

Publications62

  1. ncbi Changes in vascular dynamics of the adult rat testis leading to transient accumulation of seminiferous tubule fluid after administration of a novel 5-hydroxytryptamine (5-HT) agonist
    Jacqui Piner
    GlaxoSmithKline, Ware, Hertfordshire, SG12 ODP, UK
    Reprod Toxicol 16:141-50. 2002
    ....
  2. ncbi Synergy between combinatorial chemistry and de novo design
    A R Leach
    Glaxo Wellcome Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom
    J Mol Graph Model 18:358-67, 526. 2000
    ..We discuss how this strategy compares with and relates to alternative approaches to both structure-based library design and de novo design...
  3. ncbi Bioavailability of orally administered micronised fluticasone propionate
    C Falcoz
    Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex, England
    Clin Pharmacokinet 39:9-15. 2000
    ..The aim of this study was to determine the absolute oral bioavailability of fluticasone propionate (FP) in healthy volunteers...
  4. ncbi Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma
    P T Daley-Yates
    Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex, England
    Clin Pharmacokinet 39:39-45. 2000
    ....
  5. pmc Characterization of [(3)H]-CGP54626A binding to heterodimeric GABA(B) receptors stably expressed in mammalian cells
    A Green
    Receptor Systems Unit, Glaxo Wellcome Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY
    Br J Pharmacol 131:1766-74. 2000
    ..These data suggest that, in terms of ligand binding, the currently identified isoforms of the GABA(B) receptor are pharmacologically indistinguishable...
  6. pmc Use of two-dimensional gel electrophoresis to measure changes in synovial fluid proteins from patients with rheumatoid arthritis treated with antibody to CD4
    M A Smith
    Immunopathology, Glaxo Wellcome Research and Development plc, Stevenage, Herts SG1 2NY, United Kingdom
    Clin Diagn Lab Immunol 8:105-11. 2001
    ..Thus, the system can be used for quantitative analysis of protein expression in sites of autoimmune disease activity such as the synovial fluid of rheumatoid arthritis patients...
  7. ncbi Pyridoxal phosphate de-activation by pyrroline-5-carboxylic acid. Increased risk of vitamin B6 deficiency and seizures in hyperprolinemia type II
    R D Farrant
    Physical Sciences, GlaxoWellcome Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom
    J Biol Chem 276:15107-16. 2001
    ..Vitamin B6 de-activation may contribute to seizures in hyperprolinemia type II, which are so far unexplained, but they may be preventable with long term vitamin B6 supplementation...
  8. ncbi Epidemiology in the pharmaceutical industry: a perspective for infectious diseases
    N J Robinson
    Worldwide Epidemiology, GlaxoWellcome Research and Development, Greenford Road, Greenford, Middlesex UB6 OHE, UK
    Stat Med 19:3193-8. 2000
    ..The pharmaceutical industry is becoming increasingly committed to epidemiological research, and research agendas often involve extensive collaboration with leading external academic and public health groups...
  9. ncbi Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation
    D A Hall
    Receptor Pharmacology Unit, In Vitro Pharmacology Department, Medicines Research Centre, Glaxo Wellcome Research and Development, Stevenage, Hertfordshire, United Kingdom
    Mol Pharmacol 58:1412-23. 2000
    ....
  10. ncbi Loss of epithelial integrity resulting from E-cadherin dysfunction predisposes airway epithelial cells to adenoviral infection
    Y Man
    Cell Biology Department and Clinical Virology Department, Medicines Research Centre, GlaxoWellcome, Stevenage, United Kingdom
    Am J Respir Cell Mol Biol 23:610-7. 2000
    ..These studies show that manipulation of E-cadherin function provides a specific means of altering epithelial integrity that in turn determines resistance of airway epithelia to adenoviral infection...
  11. ncbi Involvement of cholecystokinin within craving for cocaine: role of cholecystokinin receptor ligands
    F Crespi
    Department of Biology, Glaxo Wellcome SpA, Medicines Research Centre, Via Fleming 4, 37100 Verona, Italy
    Expert Opin Investig Drugs 9:2249-58. 2000
    ..The potential therapeutic role for CCK receptor antagonists is also discussed...
  12. ncbi Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists
    A Ursini
    Glaxo Wellcome Medicines Research Centre, Via A Fleming 4, 37135 Verona, Italy
    J Med Chem 43:3596-613. 2000
    ..Moreover the introduction of bulky substituents such as adamantylmethyl at N-1 and resolution of the racemic ureas resulted in our lead compound GV150013...
  13. ncbi Application of acoustic emission to the monitoring and end point determination of a high shear granulation process
    M Whitaker
    Pharmaceutical Development, Glaxo Wellcome Research and Development, Park Road, Ware, Hertfordshire, SG12 0DP, UK
    Int J Pharm 205:79-92. 2000
    ..The technique is non-invasive, sensitive and relatively inexpensive...
  14. pmc Reverse transcriptase-PCR analysis of bacterial rRNA for detection and characterization of bacterial species in arthritis synovial tissue
    K E Kempsell
    Glaxo Wellcome Medicines Research Centre, Stevenage SG2 1NY, United Kingdom
    Infect Immun 68:6012-26. 2000
    ..The role of viable bacteria or their nucleic acids as triggers in disease onset or pathology in either RA or non-RA arthritis controls is unclear and requires further investigation...
  15. ncbi In silico research in drug discovery
    G C Terstappen
    Biology Dept, Glaxo Wellcome Medicines Research Centre, Via A Fleming 4, 37135, Verona, Italy
    Trends Pharmacol Sci 22:23-6. 2001
    ..Moreover, computational methods are being developed to predict the drug-likeness of compounds. Thus, drug discovery is already on the road towards electronic R&D...
  16. ncbi Intracellular inhibition of human neutrophil elastase by orally active pyrrolidine-trans-lactams
    S J MacDonald
    Medical Chemistry 2, Glaxo Wellcome Medicines Research Centre, Stevenage, UK
    Bioorg Med Chem Lett 11:243-6. 2001
    ....
  17. ncbi Distribution of the messenger RNA for the small conductance calcium-activated potassium channel SK3 in the adult rat brain and correlation with immunoreactivity
    S Tacconi
    GlaxoWellcome Medicines Research Centre, Molecular Medicine Unit, Via Fleming 4, 37135, Verona, Italy
    Neuroscience 102:209-15. 2001
    ....
  18. ncbi Definition of a solvent system for spherical crystallization of salbutamol sulfate by quasi-emulsion solvent diffusion (QESD) method
    M Nocent
    GlaxoSmithKline Laboratories, Pharmaceutical Development Department, Zone Industrielle n degrees 2, 23 Rue Lavoisier, 27000 Evreux, France
    J Pharm Sci 90:1620-7. 2001
    ..Finally, the influence of emulsifier concentration and of maturation time on the size of spherical particles is studied. The results show that these two parameters must be fixed to control the size of the recovered particles...
  19. ncbi Cytochrome P450 activity in control and induced long-term cultures of rat hepatocyte spheroids
    T M Walker
    Preclinical Safety Sciences, Medicines Safety Evaluation Division, GlaxoWellcome Research and Development, Park Road, Ware, SG12 0DP, Herts, UK
    Toxicol In Vitro 15:713-9. 2001
    ..The results demonstrate that rat hepatocyte spheroids retained some of the liver-specific functions essential in a long-term hepatocyte culture model, thus making spheroids comparable to other long-term culture models available...
  20. ncbi Titrating the expression of a Gi protein-coupled receptor using an ecdysone-inducible system in CHO-K1 cells
    S L Cole
    Glaxo Institute of Applied Pharmacology, Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QJ, United Kingdom
    Receptors Channels 7:289-302. 2001
    ....
  21. ncbi Development of a homogeneous MAP kinase reporter gene screen for the identification of agonists and antagonists at the CXCR1 chemokine receptor
    S Rees
    Molecular Discovery Research Unit, Glaxo Wellcome Medicines Research Centre, Hertfordshire, UK
    J Biomol Screen 6:19-27. 2001
    ..5% ethanol, 0.15% glycerol, or 1% DMSO. Signal crosstalk between adjacent wells was less than 1%. The assay exhibited a Z factor of 0.53 and a coefficient of variation of response to repeated application of IL-8 (100 nM) of 15.9%...
  22. ncbi Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: the QUEST study
    L E Goh
    Department of HIV and Opportunistic Infections, GlaxoSmithKline, Research and Development, GlaxoSmithKline, Greenford Road, Greenford, Middlesex, United Kingdom
    HIV Clin Trials 2:438-44. 2001
    ..The QUEST trial investigates this hypothesis and aims to determine whether addition of a therapeutic vaccine to HAART increases the likelihood of prolonged viral suppression compared to HAART alone...
  23. ncbi Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique
    G Young
    Division of Bioanalysis and Drug Metabolism, Glaxo Wellcome Research and Development Ltd, Ware, UK
    Xenobiotica 31:619-32. 2001
    ..06 microSv. Mass balance in recovery of administered radioactivity was achieved and information about the presence of systemically circulating metabolites was gained. 4. The future potential of the technique of AMS is discussed...
  24. ncbi Modified peptide antagonists of interleukin 5 exhibit extended in vivo persistence but restricted species specificity
    I J Uings
    Department of Cell Biology, GlaxoWellcome Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK
    Cytokine 15:10-9. 2001
    ..Despite its high potency at the human IL-5 receptor, AF18748 was unable to antagonise the activity of IL-5 on murine B13 cells, or on canine eosinophils, indicating that the peptide is highly specific for the human IL-5 receptor...
  25. ncbi The influence of lung deposition on clinical response
    J N Pritchard
    Glaxo Wellcome, Uxbridge, Middlesex, United Kingdom
    J Aerosol Med 14:S19-26. 2001
    ..Current devices have profoundly different lung deposition profiles that could affect clinical efficacy when switching devices. Devices that achieve a high lung to systemic ratio for the inhaled drug are preferable...
  26. pmc Mitochondrial toxicity and HIV therapy
    A J White
    Anti Infectives Clinical Development and Product Strategy, GlaxoSmithKline Research and Development, Greenford Road, Greenford, Middlesex, UB6 0HE, UK
    Sex Transm Infect 77:158-73. 2001
    ..Data were identified through searching of online databases including Medline and Current Contents for relevant articles, along with abstracts and posters from recent conferences in the HIV and mitochondrial fields...
  27. ncbi Computer-assisted drug development (CADD): an emerging technology for designing first-time-in-man and proof-of-concept studies from preclinical experiments
    R Gomeni
    Department of Experimental Medicine, GlaxoSmithKline Group, GlaxoWellcome S p A, Via A Fleming 2, 37135 Verona, Italy
    Eur J Pharm Sci 13:261-70. 2001
    ....
  28. ncbi Pharmacological characterisation of the human small conductance calcium-activated potassium channel hSK3 reveals sensitivity to tricyclic antidepressants and antipsychotic phenothiazines
    G C Terstappen
    Molecular Biology and Biochemistry Unit, GlaxoWellcome Medicines Research Centre, Via A Fleming 4, 37135 Verona, Italy
    Neuropharmacology 40:772-83. 2001
    ..Thus, phosphorylation of hSK3 or an accessory channel subunit seems to be involved in its modulation...
  29. ncbi The homeostatic rĂ´le of bronchoconstriction
    D I Blyth
    Respiratory Unit, Glaxo Wellcome Research and Development, Stevenage, UK
    Respiration 68:217-23. 2001
    ..In asthma, this function may be dangerously exaggerated because of the presence of unusually viscous airway secretions and the remodelling of airway walls...
  30. ncbi Methylphenylethynylpyridine (MPEP) Novartis
    F Micheli
    Glaxo Wellcome, Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
    Curr Opin Investig Drugs 1:355-9. 2000
    ..By October 1999, investigations with SIB-1757 and SIB-1893 had been discontinued in favor of MPEP [347212]...
  31. pmc Recent trends in physician diagnosed COPD in women and men in the UK
    J B Soriano
    Department of Worldwide Epidemiology, GlaxoWellcome Research and Development, Middlesex, UK
    Thorax 55:789-94. 2000
    ..Recent trends in physician diagnosed chronic obstructive pulmonary disease (COPD) in the UK were estimated, with a particular focus on women...
  32. ncbi Statistical analysis on a series of glycine antagonists
    G Tedesco
    GlaxoWellcome S p A, Verona, Italy
    Farmaco 55:194-6. 2000
    ..A significant model was obtained for both series of compounds. Structure-activity implications are discussed...
  33. ncbi Indolocarbazoles: potent, selective inhibitors of human cytomegalovirus replication
    M J Slater
    GlaxoWellcome Medicines Research Centre, Stevenage, UK
    Bioorg Med Chem 7:1067-74. 1999
    ..Compounds described in this series were generally poor inhibitors of protein kinase C betaII, and no correlation was found between the ability to inhibit HCMV and the enzyme PKC...
  34. ncbi Validation of a population pharmacokinetic/pharmacodynamic model for 5 alpha-reductase inhibitors
    P Olsson Gisleskog
    Clinical Pharmacology, GlaxoWellcome Research and Development, Greenford Road, Middlesex UB6 0HE, UK
    Eur J Pharm Sci 8:291-9. 1999
    ..Thus the model derived from single dose data from healthy volunteers was considered to be valid for the prediction of DHT levels in the patient population after repeated dosing of dutasteride and finasteride...
  35. ncbi Lack of a pharmacokinetic interaction between atovaquone and proguanil
    C Gillotin
    Laboratoire Glaxo Wellcome, Pharmacologie Clinique, Marly le Roi, France
    Eur J Clin Pharmacol 55:311-5. 1999
    ....
  36. ncbi Group I metabotropic glutamate receptors: implications for brain diseases
    F Bordi
    Pharmacology Department, GlaxoWellcome Medicine Research Centre, Verona, Italy
    Prog Neurobiol 59:55-79. 1999
    ..In this review anatomical, physiological and pharmacological results are presented with a special emphasis on the role of Group I mGluRs in functional and pathological processes...
  37. ncbi Proteomics: quantitative and physical mapping of cellular proteins
    W P Blackstock
    Biomolecular Structure Unit, Glaxo Wellcome Research and Development, Stevenage, UK
    Trends Biotechnol 17:121-7. 1999
    ..Proteomics can be divided into expression proteomics, the study of global changes in protein expression, and cell-map proteomics, the systematic study of protein-protein interactions through the isolation of protein complexes...
  38. ncbi Synthetic [5,5] trans-fused indane lactones as inhibitors of thrombin
    M Pass
    Glaxo Wellcome Research and Development, Stevenage, Herts, United Kingdom
    Bioorg Med Chem Lett 9:431-6. 1999
    ..As an example compound 11e has an apparent second order rate constant of 11 x 10(6) M(-1)sec(-1) for the inhibition of thrombin. The anticoagulant activity of these compounds is discussed...
  39. ncbi Effects of the indolocarbazole 3744W on the tyrosine kinase activity of the cytoplasmic domain of the platelet-derived growth factor beta-receptor
    I J Uings
    Cell Signalling Group, Biology Division, Wellcome Research Laboratories, Beckenham, Kent, UK
    Cell Signal 11:95-100. 1999
    ..These results suggest that, although 3744W inhibits PDGF receptor autophosphorylation directly, it can discriminate between phosphate acceptor substrates...
  40. ncbi Clinical pharmacokinetics of lamivudine
    M A Johnson
    Glaxo Wellcome Research and Development, Greenford, England
    Clin Pharmacokinet 36:41-66. 1999
    ..There is limited potential for drug-drug interactions with compounds that are metabolised and/or highly protein bound...
  41. ncbi Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group
    J P Kleim
    Clinical Virology Unit, Glaxo Wellcome, Stevenage, Herts SG1 2NY, United Kingdom
    J Infect Dis 179:709-13. 1999
    ..Therefore, sustained antiviral activity can be expected from multiple combination therapy regimens including a quinoxaline derivative...
  42. ncbi The use of microemulsion electrokinetic chromatography in pharmaceutical analysis
    M F Miola
    Pharmaceutical Development Europe, GlaxoWellcome Research and Development, Ware, Herts, UK
    J Pharm Biomed Anal 18:785-97. 1998
    ..Validation aspects such as linearity, repeatability, accuracy, injection precision and sensitivity were successfully assessed...
  43. ncbi Cibacron blue allosterically modulates the rat P2X4 receptor
    K J Miller
    Glaxo Institute of Applied Pharmacology, Department of Pharmacology, University of Cambridge, UK
    Neuropharmacology 37:1579-86. 1998
    ..5-fold). These data are consistent with the concept that cibacron blue, like zinc, allosterically regulates the function of the P2X4 receptor...
  44. ncbi A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride
    P O Gisleskog
    Division of Clinical Pharmacology, GlaxoWellcome Research and Development, Middlesex, England
    Clin Pharmacol Ther 64:636-47. 1998
    ....
  45. ncbi Isolation of translactone-containing triterpenes with thrombin inhibitory activities from the leaves of Lantana camara
    M J O'Neill
    GlaxoWellcome Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, UK
    J Nat Prod 61:1328-31. 1998
    ....
  46. ncbi Sordarin inhibits fungal protein synthesis by blocking translocation differently to fusidic acid
    J M Dominguez
    Research Department, Glaxo Wellcome SA, PTM, C Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain
    J Biol Chem 274:22423-7. 1999
    ..In agreement with this conclusion, sordarin prevented the formation of peptidyl-[(3)H]puromycin on polysomes from Candida albicans...
  47. ncbi Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome
    P P Humphrey
    Glaxo Institute of Applied Pharmacology, Department of Pharmacology, University of Cambridge, UK
    Aliment Pharmacol Ther 13:31-8. 1999
    ....
  48. ncbi The pivotal role of phosphoinositide-3 kinase in the human somatostatin sst(4) receptor-mediated stimulation of p44/p42 mitogen-activated protein kinase and extracellular acidification
    K S Smalley
    Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QJ, United Kingdom
    Biochem Biophys Res Commun 263:239-43. 1999
    ..In summary, the human sst(4) receptor is selectively desensitised by somatostatin and not by L-362855 and signals through two different PI 3-kinase linked pathways...
  49. ncbi Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine
    M J Main
    Molecular Pharmacology, Neuroscience, Glaxo Wellcome Research and Development, Stevenage, Hertfordshire, United Kingdom
    Mol Pharmacol 58:253-62. 2000
    ..Because the heteromeric KCNQ2/3 channel has recently been reported to underlie the M-current, it is likely that M-current modulation can explain the anticonvulsant actions of retigabine in animal models of epilepsy...
  50. ncbi Use of a dual firefly and Renilla luciferase reporter gene assay to simultaneously determine drug selectivity at human corticotrophin releasing hormone 1 and 2 receptors
    S J Parsons
    Receptor Pharmacology, Glaxo Wellcome Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
    Anal Biochem 281:187-92. 2000
    ..It has the potential advantage of significant time and cost savings, with application to both basic research and compound screening...
  51. ncbi Inhibition of inducible nitric oxide synthase by acetamidine derivatives of hetero-substituted lysine and homolysine
    R J Young
    Glaxo Wellcome Research and Development, Stevenage, Hertfordshire, UK
    Bioorg Med Chem Lett 10:597-600. 2000
    ....
  52. ncbi An epidemiological study to assess migraine prevalence in a sample of Italian population presenting to their GPs
    M Roncolato
    Medical Department, GlaxoWellcome, Verona, Italy
    Eur Neurol 43:102-6. 2000
    ..The study covered all the patients who visited the GPs practice, for any reason, on 5 consecutive days of 2 different weeks. A total of 71,588 patients were interviewed by 902 GPs. The prevalence of migraine in this sample was 11.6%...
  53. ncbi A regulated interaction between alpha5beta1 integrin and osteopontin
    S T Barry
    Molecular Pharmacology, Glaxo Wellcome Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, United Kingdom
    Biochem Biophys Res Commun 267:764-9. 2000
    ..These data demonstrate that thrombin cleavage regulates the adhesive properties of OPN and that alpha5beta1 integrin can interact with thrombin-cleaved osteopontin when in a high activation state...
  54. ncbi Use of routine healthcare data in safe and cost-effective drug use
    C J Currie
    Global Health Outcomes, GlaxoWellcome R and D, Greenford, Middlesex, England
    Drug Saf 22:97-102. 2000
    ..These systems cannot replace other methods of drug safety evaluation but they do offer an important adjunct to spontaneous reporting systems...
  55. ncbi Novel octaketide macrolides related to 6-deoxyerythronolide B provide evidence for iterative operation of the erythromycin polyketide synthase
    B Wilkinson
    Bioprocessing Unit, Glaxo Wellcome Research and Development, Medicines Research Centre, Stevenage, SG1 2NY, UK
    Chem Biol 7:111-7. 2000
    ..Thus, the six extension modules of the erythromycin PKS (DEBS) together catalyse the production of the specific heptaketide 6-deoxyerythronolide B...
  56. ncbi Carboxylesterases, a key factor in evaluating potential genotoxicity of Trinem antibiotics
    J Oliver
    Genetic Toxicology Department, Pre Clinical Safety Sciences, Medicine Safety Evaluation Division, Glaxo Wellcome Research and Development, Park Road, Ware, Herts SG12 0DP, UK
    Mutagenesis 15:45-55. 2000
    ..In turn this data indicates that a genotoxic hazard to humans under therapeutic conditions is unlikely...
  57. ncbi Implementation of a system for reagent selection and library enumeration, profiling, and design
    A R Leach
    Medicines Research Centre, Glaxo Wellcome Research and Development, Hertfordshire, U K
    J Chem Inf Comput Sci 39:1161-72. 1999
    ..We describe a simple statistical method for monomer selection and compare it to computationally more demanding approaches...
  58. ncbi Type of partnership and heterosexual spread of HIV infection in rural Uganda: results from simulation modelling
    N J Robinson
    INSERM Unit 88, Saint Maurice, France
    Int J STD AIDS 10:718-25. 1999
    ..At a later phase, prevention must also focus on control of transmission between longer-term HIV-discordant partners...
  59. ncbi A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo
    T P Hickling
    GlaxoWellcome Medicines Research Centre, Stevenage, GB
    Eur J Immunol 29:3478-84. 1999
    ..Intranasal administration of recombinant SP-D to RSV-infected mice inhibited replication of the virus in the lungs, reducing levels of lung virus by 80%. These results suggest that SP-D plays a major role in clearing RSV from the lungs...
  60. pmc Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract
    R J Fenton
    Glaxo Wellcome Research and Development Ltd, Stevenage, United Kingdom
    Antimicrob Agents Chemother 43:2642-7. 1999
    ..In addition, these data may be useful in the design of prophylactic protocols for humans, in that the dosing schedule may only need to be intermittent to provide protection...
  61. ncbi The 5' untranslated region of GB virus B shows functional similarity to the internal ribosome entry site of hepatitis C virus
    K Grace
    Virology, GlaxoWellcome Medicines Research Centre, Stevenage, UK
    J Gen Virol 80:2337-41. 1999
    ..Dicistronic reporter constructs were made to investigate the function of the GBV-B 5'UTR. Mutational analysis and in vitro translation experiments demonstrate that GBV-B initiates translation via an IRES...
  62. ncbi 1,4-Dioxane is not mutagenic in five in vitro assays and mouse peripheral blood micronucleus assay, but is in mouse liver micronucleus assay
    T Morita
    Tsukuba Research Laboratories, Nippon Glaxo Ltd, Ibaraki, Japan
    Environ Mol Mutagen 32:269-80. 1998
    ..It is also conceivable that the positive result in mouse liver micronucleus assay was due to a nongenotoxic mechanism, i.e., errors in genetic repair following enhancement of hepatocyte proliferation...